Novo Nordisk’s Subscription Gamble Meets a Formidable New Rival
Novo Nordisk shares fall 50% from highs as Eli Lilly’s oral GLP-1 pill challenges Wegovy. The firm launches…
Novo Nordisk’s Oral Ambitions Face a Formidable Rival and Fiscal Headwinds
Novo Nordisk touts superior weight loss & tolerability for its oral Wegovy pill vs Lilly’s Foundayo, while launching…
Novo Nordisk Responds to Rival Launch with Clinical Data and Subscription Model
Novo Nordisk releases head-to-head data favoring oral Wegovy over Foundayo and launches a direct-to-consumer subscription plan to retain…
Novo Nordisk Faces Mounting Pressure as Rival Gains Ground
Novo Nordisk faces intense competition from Eli Lilly in the $100B obesity drug market, with clinical data and…
Novo Nordisk Faces Mounting Pressure as Generic Rival Emerges
The Danish pharmaceutical giant’s commanding position in the weight-loss drug market is under significant threat. Novo Nordisk, already…